Advanced search
Publication Cover
OncoTargets and Therapy Volume 15, 2022 - Issue
Submit an article Journal homepage
112
Views
0
CrossRef citations to date
0
Altmetric
Case Report

A Novel LOC101927967 Intergenic Region ALK Fusion Identified by NGS and Validated by IHC and FISH in a Patient with Early Stage Adenocarcinoma of Lung

Xiaojing Jia1 Department of Radiotherapy, The Second Hospital of Jilin University, Changchun, People’s Republic of ChinaView further author information
,
Qianru He2 The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, People’s Republic of China;3 Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, People's Republic of China;4 The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, People's Republic of ChinaView further author information
,
Xiaodan Xing2 The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, People’s Republic of China;3 Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, People's Republic of China;4 The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, People's Republic of ChinaView further author information
,
Yanming Yang1 Department of Radiotherapy, The Second Hospital of Jilin University, Changchun, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
&
Yan Ma1 Department of Radiotherapy, The Second Hospital of Jilin University, Changchun, People’s Republic of ChinaView further author information
Pages 251-254 | Published online: 14 Mar 2022

References

  • Barlesi F, Mazieres J, Merlio J-P, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet (London, England). 2016;387(10026):1415–1426. doi:10.1016/s0140-6736(16)00004-0
  • Paliouras AR, Buzzetti M, Shi L, et al. Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition. EMBO Mol Med. 2020;12(7):e11099. doi:10.15252/emmm.201911099
  • Li W, Liu Y, Li W, Chen L, Ying J. Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in NSCLC. J Thorac Oncol. 2020;15(7):1223–1231. doi:10.1016/j.jtho.2020.02.023
  • Yip PY. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Transl Lung Cancer Res. 2015;4:165–176. doi:10.3978/j.issn.2218-6751.2015.01.04
  • Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177. doi:10.1056/NEJMoa1408440
  • Takeuchi K, Togashi Y, Kamihara Y, et al. Prospective and clinical validation of ALK immunohistochemistry: results from the Phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol. 2016;27(1):185–192. doi:10.1093/annonc/mdv501
  • Thorne-Nuzzo T, Williams C, Catallini A, et al. A sensitive ALK immunohistochemistry companion diagnostic test identifies patients eligible for treatment with crizotinib. J Thorac Oncol. 2017;12(5):804–813. doi:10.1016/j.jtho.2017.01.020
  • Smuk G, Pajor G, Szuhai K, et al. Attenuated isolated 3’ signal: a highly challenging therapy relevant ALK FISH pattern in NSCLC. Lung Cancer (Amsterdam, Netherlands). 2020;143:80–85. doi:10.1016/j.lungcan.2020.03.007
  • Marchetti A, Di Lorito A, Pace MV, et al. ALK protein analysis by IHC staining after recent regulatory changes: a comparison of two widely used approaches, revision of the literature, and a new testing algorithm. J Thorac Oncol. 2016;11(4):487–495. doi:10.1016/j.jtho.2015.12.111
  • Vendrell JA, Taviaux S, Béganton B, et al. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. Sci Rep. 2017;7(1):12510. doi:10.1038/s41598-017-12679-8
  • Cainap C, Balacescu O, Cainap SS, Pop LA. Next generation sequencing technology in lung cancer diagnosis. Biology. 2021;10(9):864. doi:10.3390/biology10090864
  • Zhang J, Zou C, Zhou C, et al. A novel Linc00308/D21S2088E intergenic region alk fusion and its enduring clinical responses to crizotinib. J Thorac Oncol. 2020;15(6):1073–1077. doi:10.1016/j.jtho.2020.03.009
  • Blackhall FH, Peters S, Bubendorf L, et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol. 2014;32(25):2780–2787. doi:10.1200/jco.2013.54.5921
  • Chaft JE, Dagogo-Jack I, Santini FC, et al. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer (Amsterdam, Netherlands). 2018;122:67–71. doi:10.1016/j.lungcan.2018.05.020
  • Liu Y, Ye X, Yu Y, Lu S. Prognostic significance of anaplastic lymphoma kinase rearrangement in patients with completely resected lung adenocarcinoma. J Thorac Dis. 2019;11(10):4258–4270. doi:10.21037/jtd.2019.09.65

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.